Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT04830501 Completed - Clinical trials for Advanced Solid Tumors

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

Start date: July 12, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.

NCT ID: NCT04727554 Completed - Clinical trials for Advanced Solid Tumors

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

Start date: April 29, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with advanced solid tumors.

NCT ID: NCT04716634 Completed - Clinical trials for Advanced Solid Tumors

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in participants with advanced or metastatic, unresectable gastric cancer (GC), or colorectal cancer (CRC) or Non-small Cell Lung Cancer (NSCLC). The study will be conducted in 2 parts. Part 1 will be the safety run-in stage to determine dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D). Part 2 will assess the preliminary efficacy of tislelizumab in combination with fruquintinib in participants as measured by the overall response rate (ORR) and other efficacy and safety profiles.

NCT ID: NCT04699929 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

Start date: January 26, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation study of the study drug YH001 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 in subjects with advanced solid tumors.

NCT ID: NCT04672460 Completed - Breast Cancer Clinical Trials

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft gel capsule) formulation after multiple dosing under fasting conditions in participants with advanced solid tumors. In addition, the effect of food on the PK of the proposed talazoparib soft gel capsule formulation will be evaluated in fixed sequence after the 2 BE assessment periods.

NCT ID: NCT04659096 Completed - Clinical trials for Advanced Solid Tumors

A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors

Start date: January 5, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.

NCT ID: NCT04577703 Completed - Clinical trials for Advanced Solid Tumors

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Start date: February 8, 2014
Phase: Phase 1
Study type: Interventional

This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors

NCT ID: NCT04481009 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Start date: August 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts.

NCT ID: NCT04393298 Completed - Clinical trials for Advanced Solid Tumors

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Start date: July 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.

NCT ID: NCT04362748 Completed - Clinical trials for Advanced Solid Tumors

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

Start date: September 15, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).